About Tenax Therapeutics
Tenax Therapeutics (NASDAQ:TENX), focuses on the development and commercialization of pharmaceutical products for critical care patients. The company's main project revolves around advancing a unique therapeutic portfolio aimed at addressing conditions with significant unmet medical needs, particularly in the cardiovascular and pulmonary domains. With a commitment to innovating in the field of medicine, Tenax Therapeutics strives to improve outcomes for patients facing life-threatening challenges, leveraging rigorous scientific research and clinical trials to bring novel treatments to the market. Their objective is not only to advance healthcare and provide effective solutions for critical care but also to become a trusted partner in enhancing patient care through their therapeutic advancements.
Snapshot
Operations
Products and/or services of Tenax Therapeutics
- Levosimendan for pulmonary hypertension associated with heart failure and preserved ejection fraction (PH-HFpEF), aimed to improve exercise capacity and symptoms.
- Imatinib for pulmonary arterial hypertension (PAH), focusing on improving hemodynamics and delaying disease progression.
- TNX-103, a long-acting formulation of Levosimendan, designed for chronic treatment of heart failure patients outside of the hospital setting.
- Collaborations on advanced therapies targeting rare cardiovascular diseases, leveraging novel compounds and delivery systems.
- Participation in clinical trials and studies to explore new indications for existing cardiovascular therapies.
- Investment in research and development of next-generation pharmacological treatments for cardiovascular diseases, emphasizing precision medicine.
Tenax Therapeutics executive team
- Mr. Christopher T. GiordanoCEO, President & Director
- Dr. Stuart Rich M.D.Chief Medical Officer & Director
- Mr. Thomas A. McGauleyCFO and Principal Financial Officer & Principal Accounting Officer
- Mr. Doug RandallChief Business Officer
- Dr. Douglas Hay Ph.D.Executive Vice President of Regulatory Affairs